Medicine details

ImageAripra 15
NameAripra 15
DosageTablet
Generic NameAprepitant
Classes Antiemetic Agent
Antivomiting Agent
Diseases
CompanyIncepta Pharmaceuticals Ltd.

Drug Package Details

Strength15 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack50
Price per pack350.00
Cost per pack308.00
Package unit10 tabs strip
Price per unit7.00
Cost per unit6.16
Discount0
Coupon
Remarks

Aprepitant

Aprepitant is a human substance P/neurokinin 1 (NK1) receptor antagonist with a selective high affinity. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, or corticosteroid receptors, which are the targets of current chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) medications (PONV) like ondansetron. palonosteron.

Aprepitant  is indicated for the prevention of-

  • Nausea and vomiting associated with highly emetogenic cancer chemotherapy
  • Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
  • Postoperative nausea and/or vomiting
  • Aprepitant can be used alone or in combination with the other anti-emetics. 
  • Aprepitant capsules in adults and pediatric patients 12 years of age and older: 125 mg on Day 1 and 80 mg on Days 2 and 3
  • Aprepitant for oral suspension in pediatric patients 6 months to less than 12 years of age or pediatric and adult patients unable to swallow capsules: 3mg/kg on day 1 with a maximum dose of 125mg. 2mg/kg on day 2 and 3 with a maximum dose of 80mg.
  •  Administer Aprepitant 1 hour prior to chemotherapy on Days 1, 2, and 3. If no chemotherapy is given on Days 2 and 3, administer Aprepitant in morning. 

Common adverse reactions in patients treated for chemotherapy induced vomiting and nausea are-

  • fatigue
  • diarrhea
  • asthenia
  • dyspepsia
  • abdominal pain
  • hiccups
  • Leukopenia
  • dehydration
  • increased alanine aminotransferase 

Clinically Significant CYP3A4 Drug Interactions

  • Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. 
    • Use of Aprepitant with other drugs that are CYP3A4 substrates, may result in increased plasma concentration of the concomitant drug.
  • Use of pimozide with Aprepitant is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.
  • Use of Aprepitant with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to Aprepitant.
  • Use of Aprepitant with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of Aprepitant. 

Decrease in INR with Concomitant Warfarin

  • Coadministration of Aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in International Normalized Ratio (INR) of prothrombin time.

Risk of Reduced Efficacy of Hormonal Contraceptives

  • Upon coadministration with Aprepitant, the efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of Aprepitant 

Contraindication

  • Contraindicated in patients hypersensitive to any component of the formulation.
  • Coadministration with pimozide is contraindicated.

 

There is no known contraindications of the preparation in terms of food and drinks.